ClinicalTrials.gg

Program

neflamapimod

Also written as “Neflamapimod” and “VX-745”.

Its studies are mostly in Lewy Body Disease · Alzheimer Disease · Ischemic Stroke · Aphasia, Primary Progressive · Huntington Disease, led by EIP Pharma.

Furthest: phase 2, since Apr 3, 20159 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
EIP Pharma91 open or runningphase 2since Apr 3, 2015Apr 3, 2015none ahead

Also a collaborator on its studies: cervomed-inc and voisin-consulting-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 3, 2015First studies: 2 phase 2 studies in Alzheimer DiseaseFirst studyNCT02423200, NCT02423122
  2. Jan 11, 2018Phase 2 study in Alzheimer DiseaseNCT03402659 · 161 enrolled · United States, Czechia, Denmark and more
  3. Jun 7, 20192 phase 2 studiesNCT04001517, NCT03980938
  4. Apr 12, 2023Phase 2 study in Lewy Body DiseaseNCT05869669 · 159 enrolled · United States, Netherlands, United Kingdom
  5. Jan 23, 2025Phase 2 study in Lewy Body DiseaseNCT06815965 · 26 enrolled · France
  6. May 5, 2025Phase 2 study in Ischemic StrokeNCT06987643 · 45 enrolled · Australia
  7. Jun 13, 2025Phase 2 study in Brain DiseasesNCT07033481 · 20 enrolled · United States, United Kingdom

TargetBeta

MAPK14 →read by rule
“MAP kinase p38 alpha inhibitor”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07033481Brain Diseases · United States, United Kingdom2Active, not recruitingSep 202620
NCT06987643Ischemic Stroke · Australia2CompletedSep 23, 202645
NCT06815965Lewy Body Disease · France2CompletedMar 11, 202626
NCT05869669Lewy Body Disease · United States, Netherlands, United Kingdom2CompletedMay 29, 2025159
NCT04001517Lewy Body Disease · United States, Netherlands2CompletedJun 30, 202091
NCT03980938Huntington Disease · United Kingdom2TerminatedOct 15, 202015
NCT03402659Alzheimer Disease · United States, Czechia, Denmark and more2CompletedJun 30, 2019161
NCT02423122Alzheimer Disease · Netherlands2CompletedJul 201616
NCT02423200Alzheimer Disease · United States2CompletedSep 201616

How it is read

Names in the registry

  • “Neflamapimod”, 4 entries
  • “neflamapimod”, 3 entries
  • “VX-745”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.